ABTAbbott Laboratories
Is it growing?
Neither accelerating nor breaking down: nothing decisive, though earnings down −54% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +4% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 17.1% now against 16.8% a year earlier.
All from SEC EDGAR, as of Mar 31, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is ABT growing?
Abbott Laboratories has grown revenue 2.8% a year over three years and 3.9% a year over five, with earnings per share compounding at 2.9%.
Revenue growth, 3-year annual rate · Medical Devices median +12% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +3.9%
Revenue growth, 5-year rate · +2.8% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +2.9%
Earnings per share, 3-year rate · revenue +2.8% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 19
Years of annual history on file · FY2007 to FY2025, as filed
Details›
- Revenue FY2021
- $43.1B
- Revenue FY2022
- $43.7B
- Revenue FY2023
- $40.1B
- Revenue FY2024
- $42.0B
- Revenue FY2025
- $44.3B
Annual income statements as filed with the SEC.
Medical Devices
The closest names by size in the same industry